Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Date:9/17/2009

    YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain
    Metastases Trial

MISSISSAUGA, Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announced that it has enrolled the first two patients in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC).

"Mexico is the 21st country to have approved nimotuzumab for marketing and, while YM's license for major market territories for nimotuzumab does not include Mexico, this approval reflects the growing recognition throughout much of the world of the value to patients of our drug and the progress being made in its commercialization," said David Allan, Chairman and CEO of YM BioSciences. "As part of YM's registration strategy for nimotuzumab, we were also pleased to report the opening of this second of two randomized, double-blind trials that YM is conducting in Canada and which are both now being expanded internationally."

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. Nimotuzumab is approved in two of the countries in YM's territories. The drug has demonstrated efficacy in clinical trials without producing the numerous and severe toxicities observed with the other marketed EGFR-targeting drugs. Mexican regulatory authorities have approved nimotuzumab for the treat
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
5. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
6. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
7. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the ... industry, recently announced the formation of the company,s Medical ... announce the addition of Dr. William E. Gannon, ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with ... variety of therapeutic areas and set strategic goals for ...
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... Jan. 26 WellCentive, LLC,today announced that WellCentive ... Information Exchange) as its patient registry and disease,management ... use of WellCentive Registry, more than 1,000 my1HIE ... will be better able to,provide preventive care services ...
... Jan. 26 Sirion Therapeutics, Inc., a privately held ... Application (NDA) for ganciclovir ophthalmic gel, 0.15%, has been ... Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir ... caused by the herpes simplex virus. The FDA has ...
... YORK, Jan. 26 Netsmart Technologies, Inc., a ... health and human services organizations, today announced it ... the New York State Association of Alcoholism and ... company,s comprehensive education, online learning and learning management ...
Cached Biology Technology:my1HIE(sm) Implements WellCentive Registry 2my1HIE(sm) Implements WellCentive Registry 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3
(Date:8/20/2014)... a burning spiciness that is irresistible to some, but ... are using their findings to develop a new drug ... caused by inflammation or other problems. They reported their ... clinical trials, in ACS, Journal of Medicinal Chemistry ... ago, scientists had pegged a compound called capsaicin as ...
(Date:8/20/2014)... chairs, synthetic rugs and plastic bags could one day ... rather than petroleum, scientists are now reporting. The novel ... the world deal with its agricultural and plastic waste ... , Athanassia Athanassiou, Ilker S. Bayer and colleagues at ... popularity is constantly growing. In 2012, its production reached ...
(Date:8/20/2014)... A new gene therapy developed by researchers at ... shown to protect mice from a life-threatening heart condition ... new therapeutic avenue," said Yi Lai, Ph.D., the leading ... the MU School of Medicine,s Department of Molecular Microbiology ... we hope this could lead to a treatment for ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2
... Using morphine to fight the pain associated with abdominal ... even tripling the amount of time it takes to ... the University of Colorado Boulder. The research team ... Grace, a postdoctoral research fellow, together with Erika Galer, ...
... from as many photons as possible is imperative. ... engineering researchers on a quest to boost the energy-absorption ... running up against limits set by the laws of ... of Pennsylvania and Drexel University have experimentally demonstrated a ...
... BURLINGTON, Mass. , Nov. 12, 2013  Decision Resources, ... for pharmaceutical and healthcare issues, finds that while most ... play a critical role in pharmaceutical development of chronic ... outside of oncology is building. The Strategic Insights report ...
Cached Biology News:Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find 2Penn and Drexel team demonstrates new paradigm for solar cell construction 2Penn and Drexel team demonstrates new paradigm for solar cell construction 3Penn and Drexel team demonstrates new paradigm for solar cell construction 4Penn and Drexel team demonstrates new paradigm for solar cell construction 5Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2
... kit for determining the absolute count of ... mobilized peripheral blood samples, and leukapheresis samples. ... nucleated cell count and a total CD45 ... for use in the BD Procount progenitor ...
... to Protein A and, until recently, no readily ... IgM purification. Standard methods for IgM purification generally ... effective for removing all of the major impurities ... Pierce has developed an easy-to-use affinity matrix ...
... compact and lightweight, the Moticam 2300 camera ... the eyepiece, eyetube, or trinocular port. Included ... use Plug-and-Play Images 2.0ML software offers quick ... tools to maximize resolution for examination or ...
... Merck KGaA. Physical form: Solution in 50% glycerol containing ... 2 , and 20 mM NaCl Preparation Unit Definition: ... acid-soluble oligonucleotides equivalent to a ΔA 260 of ... C (reaction volume 2.625 ml). Assay: SDS-PAGE ≥ ...
Biology Products: